Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we...
Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we...
Q: Patient healthcare data aggregation and analysis is seen as both the panacea for tremendous breakthroughs in precision medicine and as one of its biggest challenges. Are both true and how so? A: Dr. Jelliffe-Pawlowski: In my view, both are absolutely true – patient healthcare data...
Q: We have a long way to go with clinical trials participation. The enrollment number today is at 2-3% and that number is falling. What type and level of shift in culture, laws, collection methods, or other areas is going to be needed to accomplish...
Q: You recently recommended that colorectal cancer screening begin at age 45. How artificial intelligence and machine learning technologies might help better screen for cancer among different racial subgroups? A: Assessing risk for CRC and screening status through EMR’s has traditionally been very difficult....
Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we...
Q: You participated in the OncoArray Consortium that studied genetic variants that contribute to the risk of developing breast cancer. What were the key findings? What impact would it have on breast cancer therapies? A: The OncoArray consortium was actually studying a pre-designed array of 500K...
Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can...
Q: Patient healthcare data aggregation and analysis is seen as both the panacea for tremendous breakthroughs in precision medicine and as one of its biggest challenges. Are both true and how so? A: Certainly, aggregating and analyzing healthcare data is a big challenge, but when we...
Q: NGS is enhancing patient care through improved diagnostic sensitivity and more precise therapeutic targeting. Prominent examples include cystic fibrosis and cancer. What other clinical areas NGS will most likely to change the standard-of-care in the near future? A: Rapid turnaround newborn sequencing is going to...
